View Section: Company Analysis
Revance Rating
RT
RTI.DU stock rating score is -21/100. Revance is aExtremely Risky Investment.
The in-depth assessment covers such aspects as the profitability and solvency of the company, management efficiency, and growth sustainability. Our rating serves as an answer to whether the company`s shares are generally reasonable for purchase. The higher company rating score is, the more stock is attractive for investment.
Eyestock Rating
Last update 11.11.2024
-21/100
Low score
Rating Breakdown
Profitability score
-6
/25
Solvency score
-3
/25
Efficiency score
-25
/25
Stability score
14
/25
Revance Therapeutics Inc Rewards and Warnings
The assessment of the quality of a business is based on quantitative analysis of 10 key financials taken from the company's statements. Pay close attention to the cons, if any, before making a decision.
Financial
Check
Value
Net Profit Margin
-75 %
Earnings quality
—
—
Gross Margin
73 %
Revance Therapeutics Inc's Historical Rating
How has the company's valuation changed in the past?
A quick analysis will help you understand how stable financial indicators are overall.
Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Discover High-rated Companies
View Section: Valuation